产品名称

C 7280948

产品货号

Axon 2210 CAS [587850-67-7] MF C14H16N2O2SMW 276.35 Purity: 99% Soluble in DMSO Description Sulfone inhibitor of PRMT1 (IC50 values 12.75 μM and 26.7 μM for oligopeptide that contains the amino acids 1–21 of human histone H4 and non-histone protein Npl3 as methylation substrates respectively). Useful tool in studying the epigenetic role of PRMT1. PRMT1 has been linked to the activation of estrogen and androgen receptors as well. PRMT1 is a necessary component for oncogenic transformation induced by a mixed lineage leukemia (MLL) complex, and therefore may represent a new treatment option for hormone-dependent cancer. References Certificates Categories Extra info R. Heinke et al. Virtual Screening and Biological Characterization of Novel Histone Arginine Methyltransferase PRMT1 Inhibitors. ChemMedChem 2009, 4, 69-77. E.M. Bissinger et al. Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg. Med. Chem. 2011, 19, 3717–3731. Y Itoh et al. Small-molecular modulators of cancer-associated epigenetic mechanisms. Mol. BioSyst. , 2013, 9, 873-896. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Epigenetics Endocrinology EC 2.1.1.125 PRMT Sulfone inhibitor of PRMT1 Chemical name 4-amino-N-phenethylbenzenesulfonamide Parent CAS No. [587850-67-7] Order Size Unit Price Stock 10 mg €85.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

C 7280948

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 2210

CAS [587850-67-7]

MF C14H16N2O2S
MW 276.35

Purity: 99%
Soluble in DMSO

C 7280948

Description

Sulfone inhibitor of PRMT1 (IC50 values 12.75 μM and 26.7 μM for oligopeptide that contains the amino acids 1–21 of human histone H4 and non-histone protein Npl3 as methylation substrates respectively). Useful tool in studying the epigenetic role of PRMT1. PRMT1 has been linked to the activation of estrogen and androgen receptors as well. PRMT1 is a necessary component for oncogenic transformation induced by a mixed lineage leukemia (MLL) complex, and therefore may represent a new treatment option for hormone-dependent cancer.